Announced
Financials
Tags
Private
Friendly
Majority
Single Bidder
Pending
Merger
United States
Netherlands
drug development
Biotechnology
Synopsis
Cato Research, that specializes in drug development support for clients in the pharmaceutical, biotechnology, and medical device industries, has merged with Specialized Medical Services-oncology, a full-service CRO solely dedicated to oncology. Financial terms were not disclosed. By joining forces, CATO and SMS-oncology expand their presence across Europe and North America, deepen their oncology and regulatory expertise, and broaden their suite of services. "CATO and SMS-oncology bring a powerful blend of capabilities focused on supporting small and mid-sized biotech and pharmaceutical companies with their innovative research. Our companies share strong cultural values, anchored by a commitment to high quality and personalized customer service. Together, we're focused on growing and enhancing our services to build an industry-leading company specializing in complex therapeutic areas, including oncology, cell and gene therapy, and rare treatments," Mark Goldberg, CATO Executive Chairman.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.